The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumoursSally Thomas, Sarah Danson|British Journal of Cancer|2015Cited by 638
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Udai Banerji, Sarah P. Blagden et al.|British Journal of Cancer|2023Cited by 36
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, Rebecca Kristeleit et al.|Journal of Clinical Oncology|2019Cited by 31